Your trusted destination for CME, CPD & Medical Education across the Middle East.
WearOptimo
Professor Mark Kendall is an internationally recognized Australian biomedical engineer, scientist, inventor, and biotechnology entrepreneur. He is widely known for developing the Nanopatch, an innovative needle-free vaccine delivery technology designed to improve vaccination efficiency, accessibility, and effectiveness, particularly in low-resource communities.
He completed his Bachelor of Engineering with Honours in 1993 and earned his PhD in 1998. His academic and research career has focused on biomedical engineering, nanotechnology, drug delivery, vaccine development, and medical device innovation.
Kendall developed his research expertise through academic appointments at the University of Oxford and the University of Queensland. At the University of Queensland's Australian Institute for Bioengineering and Nanotechnology, he led research into minimally invasive methods of delivering vaccines and medicines through the skin.
His most significant scientific contribution is the Nanopatch, a small medical device containing thousands of microscopic projections that deliver vaccine directly into the immune-cell-rich layers of the skin. Unlike conventional hypodermic injections, the technology aims to improve vaccine delivery while reducing dependence on needles, refrigeration, and highly specialized administration equipment.
To commercialize this innovation, he co-founded Vaxxas in 2011. The company developed the Nanopatch platform through research partnerships and commercial collaborations, including work involving Merck and the World Health Organization.
Professor Kendall later founded WearOptimo, an Australian medical technology company developing advanced wearable sensors. Its micro-wearable technology is designed to monitor hydration and other physiological indicators, with potential applications in healthcare, sports, defence, and workplace safety.
He has also served as Vice-Chancellor's Entrepreneurial Professor at the Australian National University, where he contributes to research commercialization, entrepreneurship, and the development of medical technologies.

dmg events
dmg events